Sanofi Adr Stock Fundamentals
| SNY Stock | USD 54.15 2.00 3.84% |
Sanofi ADR fundamentals help investors to digest information that contributes to Sanofi ADR's financial success or failures. It also enables traders to predict the movement of Sanofi Stock. The fundamental analysis module provides a way to measure Sanofi ADR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanofi ADR stock.
At this time, Sanofi ADR's Selling General Administrative is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 6.3 B in 2025, whereas Depreciation And Amortization is likely to drop slightly above 3.2 B in 2025. Sanofi | Select Account or Indicator |
Sanofi ADR Company Return On Equity Analysis
Sanofi ADR's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sanofi ADR Return On Equity | 0.0582 |
Most of Sanofi ADR's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sanofi Return On Equity Historical Pattern
Today, most investors in Sanofi ADR Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sanofi ADR's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's return on equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sanofi ADR return on equity as a starting point in their analysis.
Sanofi ADR Return On Equity |
| Timeline |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Sanofi Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Sanofi ADR has a Return On Equity of 0.0582. This is 100.24% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 118.77% lower than that of the firm.
Sanofi ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sanofi ADR's current stock value. Our valuation model uses many indicators to compare Sanofi ADR value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sanofi ADR competition to find correlations between indicators driving Sanofi ADR's intrinsic value. More Info.Sanofi ADR is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.71 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sanofi ADR is roughly 1.40 . At this time, Sanofi ADR's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sanofi ADR's earnings, one of the primary drivers of an investment's value.Sanofi ADR's Earnings Breakdown by Geography
Sanofi Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi ADR's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi ADR could also be used in its relative valuation, which is a method of valuing Sanofi ADR by comparing valuation metrics of similar companies.Sanofi ADR is currently under evaluation in return on equity category among its peers.
Sanofi ADR ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sanofi ADR's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sanofi ADR's managers, analysts, and investors.Environmental | Governance | Social |
Sanofi Fundamentals
| Return On Equity | 0.0582 | ||||
| Return On Asset | 0.0416 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 150.89 B | ||||
| Shares Outstanding | 2.51 B | ||||
| Shares Owned By Institutions | 11.30 % | ||||
| Number Of Shares Shorted | 5.29 M | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.72 X | ||||
| Price To Sales | 2.75 X | ||||
| Revenue | 46.03 B | ||||
| Gross Profit | 33.48 B | ||||
| EBITDA | 12 B | ||||
| Net Income | 5.4 B | ||||
| Cash And Equivalents | 6.9 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 18.42 B | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 1.30 X | ||||
| Book Value Per Share | 58.10 X | ||||
| Cash Flow From Operations | 10.26 B | ||||
| Short Ratio | 2.17 X | ||||
| Earnings Per Share | 1.87 X | ||||
| Price To Earnings To Growth | 0.96 X | ||||
| Target Price | 62.63 | ||||
| Number Of Employees | 86.09 K | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 133.18 B | ||||
| Total Asset | 126.46 B | ||||
| Retained Earnings | 67.5 B | ||||
| Working Capital | 6.46 B | ||||
| Current Asset | 24.93 B | ||||
| Current Liabilities | 16.82 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 3.85 % | ||||
| Net Asset | 126.46 B |
About Sanofi ADR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanofi ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi ADR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 686.5 M | 652.2 M | |
| Total Revenue | 52.9 B | 31.3 B | |
| Cost Of Revenue | 16.4 B | 9.3 B | |
| Stock Based Compensation To Revenue | 0.00 | 0.01 | |
| Research And Ddevelopement To Revenue | 0.17 | 0.19 | |
| Capex To Revenue | 0.08 | 0.07 | |
| Revenue Per Share | 33.10 | 18.37 | |
| Ebit Per Revenue | 0.15 | 0.22 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sanofi Stock Analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.